› A "Things I Won't Work With" Request
› A 2.3 Billion Dollar Attention-Getter
› A 200-Proof Shot of Medicinal Chemistry
› A Bad Assay: Better Than None?
› A Birthday Worth Noting
› A Bit More Garage Biotech
› A Blogroll Update
› A Break, Whether I Felt Like It Or Not
› A Breath of Fresh Air from Fuji
› A Brief Note on Current Events
› A Brief and Not At All Intemperate Evaluation of the Current Literature
› A Capacious Rat-Hole Indeed
› A Cautionary Tale
› A Certain Tension in the Air
› A Chemical Wish List
› A Clean Lab is A Happy Lab
› A Cold-Weather Recipe, By Request: Onion Soup
› A Complete Diversion: Purple Compounds
› A Couple of Days Off
› A Cure for the Common Cold? Don't. . .Ah, Hold Your Breath
› A DPP-IV Compound Makes It Through
› A Database of Side Effects
› A Day With All the Bark Left On It
› A Day at the Rota-Vap
› A Day in the Life of Peter Rost
› A Day in the Life: Dichloromethane and Peanut Butter
› A Deuterium Deal
› A Dish Best Served Cold
› A Drug's Target, Finally
› A Farewell to Tin
› A Few More Victories Like This, And We Will Be Undone
› A Few Questions For My Fellow Pharma Chemists
› A Few Words
› A Fire, And Its Flames
› A First Step Toward A New Form of Life
› A Former Pfizer Executive Finally Trashes Pfizer's Strategy
› A Friday Book Recommendation
› A Friday Linkfest
› A GSK/Sirtris Wrap-Up
› A Good Day's Work
› A Google Oddity
› A Green Fluorescent Nobel Prize
› A Landmark In Clinical Trial Data Interpretation
› A Last-Ditch Effort - Or Is It?
› A Law of the Lab: Yields and Variations
› A Lengthy Day
› A Less-Than-Subtle Plan
› A Little Ambiguity Would Be Welcome Right About Now
› A Long Tail Indeed
› A Look Inside the Compound Collections
› A Look Into the Future?
› A Look Under the Hood
› A Man, A Book, and a Plan. Several Plans.
› A Mechanism for Thimerosal
› A Med-Chem Book Recommendation
› A Meditation on Solvents
› A Modest Literature Proposal
› A Mystery Gas?
› A Natural Wonder Drug - Now What?
› A New Book on Chemical Patents
› A New Cancer Target - Maybe
› A New FDA?
› A New Form of Hype, uh, Life?
› A New HIV Therapy. Yawn?
› A New Route to Tamiflu?
› A New Way to Approve Drugs
› A Nobel For Palladium Couplings, At Last
› A Nobel for Ribosome Structure
› A Nobel for Telomerase
› A Note About Identity Spoofing
› A Note to Andy Grove
› A Piece of the Action
› A Pile of Malaria Leads For the Taking
› A Post I've Been Looking Forward to For Months
› A Postdoc's Lament
› A Quasicrystal Nobel Prize
› A Question For the Audience
› A Question For the Crowd
› A Quick And Nerdy Question
› A Quick Glassware Question
› A Quick One While He's Away
› A Quick Quiz (Re: Antibacterials)
› A Quick Tour Through the Mudhole
› A Quick Tour Through the Mudhole
› A Race to the Bottom
› A Radiation Chart to Clip and Save
› A Rake's Progress
› A Re-Org at Novartis
› A Real Genetic Headscratcher
› A Real-World Can O' Worms
› A Request From Biology
› A Resveratrol Research Scandal. Oh, Joy.
› A Rough Business
› A Salute
› A Science Writing Award
› A Scientific Aptitude Test?
› A Scientist's Resolutions
› A Scorched-Earth Policy at Wyeth's Princeton Site?
› A Sensitive Guy
› A Shortage of Cancer Drugs?
› A Shot Across the Bow
› A Smelly Riddle
› A Solution, Courtesy of the MIT Faculty
› A Spin of the Wheel
› A Spray-Painted Crystal Ball
› A Startlingly Good Leukemia Trial
› A Steeplechase of Dead Horses
› A Storm in a Teacup
› A Strange Compound, In Strange Places
› A Synthetic Genome; A New Species
› A Tale of Two Trials
› A Technical Question
› A Tiny Little Presentation Tip
› A Treadmill Pill?
› A Trial Too Far
› A Twisty Road
› A Vaccine Against Putting on Weight?
› A Vioxx Bomb Drops. Or Does It?
› A Visit To Academia
› A Week in the Life
› A Whistleblowing Record
› A Word to the Wise
› A Word to the Wise About TGN1412
› ACC2: Great Metabolic Target, Or Total Bust?
› ACS Med Chem Letters
› ACS Meetings
› ACS Survey - Or Something Else?
› AGI-1067: Dead or Alive?
› ASCO Fever
› Abbott Cuts the Drug Business Loose
› Abbott's Cutting Jobs
› About Time
› Abstract Abstracts
› Academia and Industry, Suing Each Other
› Academia in Summertime
› Academic Drug Discovery: A Survey
› Access To Science
› Access to Phase I Drugs: A Constitutional Right?
› Acorda and Ampyra
› Acronym-Fest: GSK and Its DPUs
› Actually, It's Everything Else That's Off-Topic
› Adam Smith Goes Pharmaceutical
› After Natural Selection's Through With You
› Again, What's It Worth to You?
› Against Panic
› Ah, Glassware
› Ah, It's Fine. Just Send the Darn Thing Out Already.
› Ah, Marketing
› Ah, Politics
› Ah, Remember Those Days? How Will We Remember These?
› Ah, Rumors
› Ah, the Heck With the Error Bars
› Ahem: "Sell Gobs of Dope"?
› Airplanes and Chemicals
› Akt and Mek, But Not PDQ
› Alas, Dendreon
› Albany Molecular Cuts - In the US, Anyway
› Alex Tabarrok on Me-Too Drugs
› Alexander Would Have Understood
› All Bets Are Now Officially Off
› All Fixed Up
› All Natural
› All Of You Industrial Scientists: Out Of the Room
› All Quiet on the Genzyme Front?
› All Sorts of Holes
› All The Fat Cells You'll Ever Have - Sort Of
› All Those Worthless Papers
› All the Myriad Ways
› All the Not-So-Myriad Ways
› Alli: "Underwhelming"
› Allons Pharmas de la Patrie!
› Alnylam Cuts Back Hard
› Altermune - Real Stuff or Not?
› Aluminum: Friend or Foe?
› Always Read the Fine Print
› Alzheimer's Markers and Collaboration
› Alzheimer's Vaccine Refuses to Die
› Alzheimer's and Amyloid, Again
› Alzheimer's: A Report From the Front
› Alzheimer's: Down With Amyloid?
› Alzheimer's: Extracting Data From Failed Trials
› Alzheimer's: The News Is Not Getting Better
› Am I Blue?
› Amazing Stuff! Guess Where It's From. . .
› Amgen's New Patent: Explanations, Anyone?
› Amgen: Brace Yourselves
› Amgen: The Pythian Oracle Laughs Again
› Amyloid in Trouble
› An Alternative Prescription From Chopra, Roy, and Weil
› An Alzheimer's Compound Runs Into Big Trouble
› An Antiviral Example
› An Economist Who Gets It
› An Enzyme Inhibitor You Have Never, Ever, Considered
› An Era Begins
› An Expensive Way Back for Celebrex
› An Experiment in Progress?
› An Eye For the Numbers
› An HIV Drug. Or A Gout Drug? Or Both. . .
› An Impressive Nanolist of Nanocitations
› An Innocent Question
› An NMR Poster
› An Off-Topic Ramble
› An Outsourcing Blast
› An Unethical Clinical Trial
› An Update
› Anarchy in the EU
› Ancient Chemistry Comes Back to Life?
› Ancient Metals
› And 0.04 Molar in Eye of Newt. . .
› And All For a Little Money
› And Always Keep Ahold of Nurse, For Fear of Finding Something Worse
› And Another Thing
› And Another Thing. . .
› And Another Thing. . .
› And I Still Have Some of Those Shirts
› And It Goes Like This
› And It Goes Like This!
› And Now A Word. . .
› And Now Some Politics
› And Now for Something Completely Different
› And Now, the Retractome
› And One Was Just Right?
› And So, 2011
› And Speaking of Discovering Things. . .
› And That Is That
› And The Winner Is. . .
› And Thee, O Time
› And While We're On the Subject - Mercury?
› And While We're Talking About Industry-Sponsored Studies. . .
› And You Thought Exubera Was A Disaster Before
› And a Quick Political Note
› And on the Carl Icahn Front. . .
› Andrew Witty's Advice
› Andy Grove's Idea For Opening Up Clinical Trials
› Andy Grove: Rich, Famous, Smart and Wrong
› Aneuploidy, or What're A Few Chromosomes, More or Less?
› Ang. Chem. Gets Weirder Every Day
› Angell's Book
› Angiogenesis Inhibitors: Helping or Hurting?
› Angiotensin Receptor Blockers and Cancer: For Real?
› Animal Models: How High to Set the Bar?
› Animal Rights, You Say?
› Animal Studies: Are Too Many Never Published At All?
› Animal Testing: A View From the Labs
› Anonymity?
› Another Alzheimer's Compound Goes Down
› Another Blogroll Update
› Another Chemistry Prize for Biology
› Another Cholesterol Medication Goes Down (Or Does It)?
› Another Cold-Weather Recipe: Chicken Pot Pie
› Another Iron Reaction Hits The Mat
› Another Law of the Lab
› Another New Med-Chem Journal
› Another Obesity Drug? Not Likely.
› Another Pop Quiz!
› Another Proposal For the Scientific Literature
› Another Sack of Raving Nonsense Is Slated For Publication
› Another Set of Eyes
› Another Shot
› Another Shot Across the Bow
› Another Shot at Cancer
› Another Snow Day
› Another Stuffed Shirt
› Another Take on the Munos Paper
› Another Thing We Don't Know
› Another Thing You'd Think Would Be Simple
› Another Two-Person Drug Company
› Another Zero-Palladium Delusion?
› Anticoagulants, One After Another
› Antidepressants: Depressing News or Not?
› Antioxidants and Cancer: Backwards?
› Antipsychotics: Do They Work For A Completely Different Reason?
› Antisoma's Phase III Disaster
› Antivirals "Gathering Dust"?
› Anyone from GSK Interested?
› Anything Worth Doing. . .
› ApoE4: Test or Not?
› Apotex's Plavix Adventure: Four Years Later
› Applied Organic Synthesis: Chocolate Pecan Pie
› Arcadia's Furnishings
› Archaeologists Announce Dirty Laundry Discovery
› Ardea's Gout Drug Progresses
› Are Genes Patentable Or Not?
› Are You Experienced?
› Are You Now, Or Have You Ever Been. . .?
› Arena / Lorcaserin Update
› Arena, Lorcaserin, and the FDA
› Argumentum ad Crumenam
› Ariad Loses on Appeal
› Ariad Wins a Round
› Ariad's Day in Court
› Ariad's Patent Eviscerated
› Ariad's Patent Rises From the Grave to Smite the Living
› Ariad's Patent: A Court Rules
› Ariad's Patent: Let Us Now Dance In Circles
› Aromatherapy
› Around and About
› Arr, Me Hearties!
› Ars Longa, But Instructions to Authors Say "Brevis"
› Arsenic Bacteria Ride Again. (Or Don't).
› Arsenic Bacteria: Does The Evidence Hold Up?
› Arsenic in DNA: The Kinetic Argument.
› Arsenic, Patents, and the World
› Arzoxifene: Not the Road to Big Profits?
› As Goes ASCO. . .
› As Merck Caroms Off Another Tree
› As Others See Us
› As Thin As a Soap Bubble
› Ask Not
› Astellas Buys Out OSI
› Astellas and OSI: Nothing like MLNM/Takeda?
› AstraZeneca Cutting Even More?
› AstraZeneca Layoffs and Closings
› AstraZeneca Makes Its Move
› AstraZeneca Tears 'Em Down
› AstraZeneca in Waltham
› AstraZeneca's Problems
› At My Desk, Playing 500-Card Stud
› At Your Newsstand Today
› Attack of the Angry Viruses
› Attitude
› Auroral Activity
› Autism and Vaccines: Boiling Over Yet Again
› Avandia Goes Down: A Research Rant
› Avandia Goes Out
› Avandia's Latest Round
› Avandia: Going Under for the Third Time?
› Avandia: Off the Market or Not?
› Avandia: Trouble or Not?
› Avandia: Trouble, Run Head to Head
› Avandia: Was the Evidence Buried?
› Avastin At the FDA Today: Passion Should Lose
› Avastin Coverage, Amended
› Avastin For Metastatic Breast Cancer: The Whole Story
› Avastin and Medicare
› Avastin's Metastatic Breast Cancer Approval Revoked
› Avastin's Numbers
› Avastin: False Hope for Metastatic Breast Cancer
› Avastin: Taking It Back
› Aventis: Is It Genzyme?
› Awash in Yen
› Awful, No Doubt. But Not As Awful as Before?
› Awkward Conversations